Drugs / QL1209
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07861139 | Oct 2026 → Apr 2027 expected | breast cancer | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT04629846 | Nov 2020 → Aug 2022 | breast cancer | Qilu Pharmaceutical Co., Ltd. | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QL1209 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04629846 ↗ |
| Modality | Monoclonal antibody | “Recombinant anti-HER-2 domain Ⅱ humanized monoclonal antibody injection” NCT04629846 ↗ |
| Route | Intravenous | “QL1209 IV infusion” NCT04629846 ↗ |